Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator
Xintela (XINT) announces that Xintela’s oncology subsidiary, Targinta AB, has today initiated a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator in New York, USA, for development of its integrin α10β1 antibody therapeutic in patients with aggressive sarcoma. Under the collaboration, Targinta will produce antibodies targeting integrin α10β1 and complete preclinical development work […]
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of […]
Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products
Xintela and EQGen Biomedical Inc. (“EQGen”) have signed the definitive collaboration and license agreement, contemplated by their previously announced term sheet, for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and […]
Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study
Xintela’s interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend […]
Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million
Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s […]
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]
Targinta plans Phase 0 clinical study
Targinta’s Board of Directors has decided to focus development of the company’s therapeutic antibodies on a so-called clinical Phase 0 study (microdosing study) in cancer patients. The purpose of the clinical Phase 0 study is to show, with a very low dose of labeled antibodies, that they target the tumor and thus validate Targinta’s proprietary […]
Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers
Xintela has today received approval from the Medical Products Agency for a clinical Phase I/IIa study with XSTEM in patients with difficult-to-heal venous leg ulcers. XSTEM consists of integrin α10β1-selected and quality-assured mesenchymal stem cells and is produced in Xintela’s own GMP facility. In the clinical study, which will be carried out in collaboration with […]
Xintela AB Interim Report January – March 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2022» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 11,042 (loss: 9,047).» Loss per share* was SEK 0.12 (loss: 0.12).» At March 31, 2022, the equity/assets ratio** was -36 % (16). * Earnings/loss […]
